CA2843195A1 - Analogues d'heterocyclyl-pyrimidine en tant qu'inhibiteurs de jak - Google Patents

Analogues d'heterocyclyl-pyrimidine en tant qu'inhibiteurs de jak Download PDF

Info

Publication number
CA2843195A1
CA2843195A1 CA2843195A CA2843195A CA2843195A1 CA 2843195 A1 CA2843195 A1 CA 2843195A1 CA 2843195 A CA2843195 A CA 2843195A CA 2843195 A CA2843195 A CA 2843195A CA 2843195 A1 CA2843195 A1 CA 2843195A1
Authority
CA
Canada
Prior art keywords
amino
pyrazol
pyrimidin
chloro
hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2843195A
Other languages
English (en)
Inventor
Jay Freeman
Valerie Reader
Glynn Addison
Nigel Ramsden
Jane Elizabeth Scanlon
Richard John Harrison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellzome Ltd
Original Assignee
Cellzome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ltd filed Critical Cellzome Ltd
Publication of CA2843195A1 publication Critical patent/CA2843195A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
CA2843195A 2011-07-28 2012-07-24 Analogues d'heterocyclyl-pyrimidine en tant qu'inhibiteurs de jak Abandoned CA2843195A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11175807 2011-07-28
EP11175807.4 2011-07-28
US201261635921P 2012-04-20 2012-04-20
US61/635,921 2012-04-20
PCT/EP2012/064515 WO2013014162A1 (fr) 2011-07-28 2012-07-24 Analogues d'hétérocyclyl-pyrimidine en tant qu'inhibiteurs de jak

Publications (1)

Publication Number Publication Date
CA2843195A1 true CA2843195A1 (fr) 2013-01-31

Family

ID=47600533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2843195A Abandoned CA2843195A1 (fr) 2011-07-28 2012-07-24 Analogues d'heterocyclyl-pyrimidine en tant qu'inhibiteurs de jak

Country Status (9)

Country Link
US (1) US20140179664A1 (fr)
EP (1) EP2736901A1 (fr)
JP (1) JP2014521623A (fr)
KR (1) KR20140047092A (fr)
CN (1) CN103781780B (fr)
AU (1) AU2012288892B2 (fr)
BR (1) BR112014000360A2 (fr)
CA (1) CA2843195A1 (fr)
WO (1) WO2013014162A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
EP2822935B1 (fr) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase c-jun-terminale (jnk)
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (fr) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Inhibiteurs polycycliques de la kinase cycline-dépendante 7 (cdk7)
WO2015164614A1 (fr) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
WO2015164604A1 (fr) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
WO2016105528A2 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
EP4019515A1 (fr) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
WO2017087905A1 (fr) 2015-11-20 2017-05-26 Denali Therapeutics Inc. Composés, compositions, et procédés
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
CR20220182A (es) 2016-06-16 2022-06-15 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592)
AU2018337138B2 (en) * 2017-09-21 2021-04-01 Beijing Scitech-Mq Pharmaceuticals Limited 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CN113214230B (zh) * 2017-09-21 2022-10-04 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN110734427B (zh) * 2018-07-20 2021-01-15 北京赛特明强医药科技有限公司 含烯基的嘧啶甲酰胺类化合物、组合物及其应用
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
WO2020118683A1 (fr) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
LT3966206T (lt) * 2019-05-10 2023-11-10 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidino amido autofagijos inhibitoriai ir jų naudojimo būdai

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0961780B1 (fr) 1997-02-12 2007-04-11 Electrophoretics Limited Proteines-marqueurs pour le cancer du poumon et utilisation de ces dernieres
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1054004B1 (fr) 1997-12-15 2008-07-16 Astellas Pharma Inc. Nouveaux derives de pyrimidine-5-carboxamide
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
WO2001042246A2 (fr) 1999-12-10 2001-06-14 Pfizer Products Inc. Composes a base de pyrrolo[2,3-d]pyrimidine
WO2001060814A2 (fr) 2000-02-15 2001-08-23 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
US20080194606A1 (en) * 2005-05-05 2008-08-14 Astrazeneca Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
WO2006134056A1 (fr) 2005-06-14 2006-12-21 Cellzome Ag Procede d'identification de nouveaux composes interagissant avec les enzymes
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
DK1862802T3 (da) 2006-06-01 2009-04-14 Cellzome Ag Fremgangsmåde til identifikation af med ZAP-70 vekselvirkende molekyler og til rensning af ZAP-70
BRPI0715418A2 (pt) 2006-07-21 2013-03-26 Novartis Ag compostos de 2,4-di(arilaminio)-pirimidina-5-carboxamida como inibidores de cinases jak
WO2008060301A1 (fr) 2006-11-16 2008-05-22 Pharmacopeia , Llc Dérivés de purine substitués en 7, destinés à l'immunosuppression
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
WO2008132502A1 (fr) * 2007-04-25 2008-11-06 Astrazeneca Ab Pyrimidines substitués par pyrazolyle-amino et leur utilisation dans le traitement du cancer
WO2009008992A2 (fr) 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Traitement anticancéreux en combinaison
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2419423A1 (fr) 2009-04-14 2012-02-22 Cellzome Limited Composés de pyrimidine substitués par fluoro en tant qu'inhibiteurs de jak3
KR20120102601A (ko) * 2009-10-20 2012-09-18 셀좀 리미티드 Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체

Also Published As

Publication number Publication date
WO2013014162A1 (fr) 2013-01-31
EP2736901A1 (fr) 2014-06-04
AU2012288892B2 (en) 2016-04-21
CN103781780B (zh) 2015-11-25
KR20140047092A (ko) 2014-04-21
AU2012288892A1 (en) 2014-02-20
BR112014000360A2 (pt) 2017-02-14
CN103781780A (zh) 2014-05-07
JP2014521623A (ja) 2014-08-28
US20140179664A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
AU2012288892B2 (en) Heterocyclyl pyrimidine analogues as JAK inhibitors
AU2012357038B2 (en) Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US9242987B2 (en) Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
WO2013017480A1 (fr) Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
EP2566867A1 (fr) Composés de pyrazole comme inhibiteurs de jak
CA2815330A1 (fr) Composes de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2
US9040545B2 (en) Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
CA2758614A1 (fr) Composes de pyrimidine substitues par fluoro en tant qu'inhibiteurs de jak3
CA2849340A1 (fr) Derives de pyrazolo[4,3-c]pyridine comme inhibiteurs de kinases
CA2875990A1 (fr) Analogues heterocyclyle de pyrimidine comme inhibiteurs de tyk2
US20120172385A1 (en) Ortho substituted pyrimidine compounds as jak inhibitors
WO2012143320A1 (fr) Composés (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine comme inhibiteurs de la jak3
US20140296234A1 (en) Pyrimidine derivatives as mtor inhibitors
WO2013017479A1 (fr) Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
RU2564419C1 (ru) Гетероциклические аналоги пиримидина в качестве ингибиторов jak
AU2011246596A1 (en) Pyrazole compounds as JAK inhibitors
EP2606050A2 (fr) Analogues de la hétérocyclyl pyrazolopyrimidine comme inhibiteurs sélectifs de la jak

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170725